TIVOLI represents our belief that true innovation grows from trust, integrity, andleadership — delivering value and better outcomes for patients.

Quality

Patient Well-Being

Tivoli Therapeutics is committed to the well-being of patients in Asia by delivering high-quality medicines across various therapeutic areas.

Thoughtful

Broad Generics Portfolio

Within our imported generics businesses, our large portfolio of more than 30 different molecules consists of niche generics, difficult-to-develop medicines, and value-added presentations. We commercialize them either directly or through wholesaler partnerships.

GROWTH

Proven Expertise

Since the company was founded, we have license in more than 30 molecules, gaining thereby a very strong expertise on which we continue to capitalise day after day.

developments

Active Pipeline

We are very active in BD and Development as well, with an ongoing pipeline currently including more than 50 projects. This allows us to bring several new projects to market every quarter.

GLOBAL

Expanding Asia Footprint

While highly responsive to its domestic market in Taiwan, Tivoli Therapeutics also keeps expanding its Asia footprint and currently operates in Singapore and Malaysia where we have our own commercial affiliates. We are expanding into Indonesia, Vietnam, the Philippines, Thailand, Hong Kong in future.

Milestone of Tivoli

Since Tivoli established...

 

  • Our success story since 2023
  • Within just a year and a half, we have successfully built a clear and sustainable business operation model.
  • Starting from Q4 2023, we focused on securing the necessary funding to lay a solid foundation for growth.
  • By the first half of 2024, our efforts shifted toward defining the product strategy and establishing a viable business model.
  • By the end of 2024, we achieved key milestones in market validation and commercial readiness.
  • Entering 2025, our priority in the first quarter has been team expansion and organizational development — strengthening collaboration and expertise across functions to prepare for large-scale operations.
  • From late 2025 through early 2027, the company will transition into a phase of stable growth, optimizing capital deployment, expanding the product portfolio, and reinforcing the leadership and execution capacity of our core team.
  • In 2027, at least 6 products will be launched in Taiwan

 

Through this structured timeline, we have not only established a well-defined operational framework but also built a business model that is positioned for long-term growth

 

Our Corporate Values

  • Integrity in Every Molecule

    We uphold the highest ethical and regulatory standards in all research, manufacturing, and commercial activities — because patient safety and trust come first.

  • Science-Driven Innovation

    We innovate with purpose — translating strong science into accessible, high-quality medicines that improve patient outcomes worldwide.

  • Uncompromising Quality

    From API to finished dosage form, quality is not an act — it’s our discipline. Every batch reflects our commitment to global GMP excellence.

  • Collaboration for Better Health

    We believe partnership accelerates progress. We work closely with clinicians, regulators, and partners to deliver real therapeutic value.

  • Sustainability and Global Impact

    We pursue long-term growth that benefits patients, communities, and the planet — integrating sustainability into every decision.